



**B**

Treatment	SUCRA	PrBest	Mean rank
Met+TZD	87.6	47.2	2.2
TZD	65.7	15.3	4.4
Met	60.0	0.4	5
SGLT2i	54.8	11.3	5.5
DPP4i	51.6	2	5.8
SU	48.8	1.7	6.1
Met+GLP-1RA	47.3	2.9	6.3
Met+DPP4i	37.8	4.3	7.2
Placebo	38.5	1.2	7.2
GLP-1RA	34.6	13.3	7.5
DPP4i+SGLT2i	23.4	0.4	8.7

**Supplementary Fig. 9.** Network geometry (A) and the results of rank test (B) for effect on high-density lipoprotein (HDL) cholesterol of antidiabetic treatments after 6 months. (A) Each circle represents an antidiabetic treatment that was included in the analysis, with the size of the circle proportional to the number of trials involving the treatment. The width of each connecting line is proportional to the number of subjects who participated in each pair of trials. The global test for inconsistency yielded a  $P$  value of  $<0.0001$ , which suggests that there may be significant inconsistencies present in the network of treatments. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for effect on high-density lipoprotein cholesterol (mg/dL) of antidiabetic treatments after 6 months. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in reverse order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonylurea. <sup>a</sup>It results indicate statistical significance.

(Continued to the next page)

Supplementary Fig. 9. Continued

C

	DPP4i+SGLT2i	GLP-1RA	Placebo	Met+DPP4i	Met+GLP-1RA	SU	DPP4i	SGLT2i	Met	TZD	Met+TZD
DPP4i+SGLT2i	DPP4i+SGLT2i	0.2 (-13.8 to 14.2)	1.7 (-4.6 to 8.0)	1.4 (-6.9 to 9.7)	2.3 (-5.2 to 9.8)	2.4 (-4.6 to 9.5)	2.6 (-2.1 to 7.3)	2.7 (-1.7 to 7.1)	-2.8 (-6.90 to 1.2)	3.9 (-4.0 to 11.8)	6.0 (-1.4 to 13.4)
GLP-1RA		GLP-1RA	1.5 (-11.8 to 14.8)	1.2 (-12.5 to 14.9)	2.1 (-11.1 to 15.3)	2.2 (-10.8 to 15.3)	2.4 (-10.8 to 15.6)	2.5 (-11.5 to 16.5)	-0.3 (-5.6 to 5.1)	3.7 (-9.8 to 17.2)	5.8 (-7.4 to 19.1)
Placebo		0.4 (-0.6 to 1.4) <i>I</i> <sup>2</sup> =0.0% 1 study	Placebo	-0.3 (-7.2 to 6.5)	0.6 (-5.3 to 6.4)	0.7 (-4.6 to 6.1)	0.9 (-3.3 to 5.1)	1.0 (-5.3 to 7.3)	0.6 (-3.5 to 4.6)	2.2 (-4.2 to 8.6)	4.3 (-1.5 to 10.1)
Met+DPP4i			-1.2 (-2.9 to 0.5) <i>I</i> <sup>2</sup> =0.0% 1 study	Met+DPP4i	0.9 (-5.9 to 7.7)	1.1 (-5.3 to 7.4)	1.2 (-5.6 to 8.0)	1.3 (-7.0 to 9.6)	-1.5 (-8.3 to 5.3)	2.5 (-4.8 to 9.8)	4.6 (-2.1 to 11.4)
Met+GLP-1RA				Met+GLP-1RA	0.2 (-5.2 to 5.4)	0.3 (-5.5 to 6.1)	0.4 (-7.1 to 7.9)	1.8 (-3.6 to 7.2)	1.6 (-4.8 to 8.0)	3.7 (-2.0 to 9.5)	
SU					SU	0.2 (-5.1 to 5.4)	0.3 (-6.8 to 7.3)	3.0 (-9.6 to 15.6)	1.5 (-4.4 to 7.3)	3.6 (-1.6 to 8.8)	
DPP4i	-2.6 (-5.4 to 0.2) <i>I</i> <sup>2</sup> =0.0% 1 study	0.0 (-0.7 to 0.7) <i>I</i> <sup>2</sup> =29.0% 7 studies	0.3 (-1.1 to 1.7) <i>I</i> <sup>2</sup> =0.0% 1 study				DPP4i	0.1 (-4.6 to 4.8)	5.7 (-0.5 to 12.0)	1.3 (-5.0 to 7.6)	3.4 (-2.3 to 9.1)
SGLT2i	-2.7 <sup>a</sup> (-5.0 to -0.4) <i>I</i> <sup>2</sup> =0.0% 1 study	-2.7 <sup>a</sup> (-3.4 to -1.9) <i>I</i> <sup>2</sup> =60.4% 5 studies					-2.9 <sup>a</sup> (-3.8 to -2.1) <i>I</i> <sup>2</sup> =76.6% 2 studies	SGLT2i	3.2 (-3.0 to 9.4)	1.2 (-6.7 to 9.1)	3.3 (-4.1 to 10.8)
Met		-3.0 (-15.0 to 9.0) <i>I</i> <sup>2</sup> =0.0% 1 study	-0.7 (-2.3 to 0.8) <i>I</i> <sup>2</sup> =82.3% 2 studies	-0.5 (-1.8 to 0.8) <i>I</i> <sup>2</sup> =0.0% 2 studies	-0.9 (-2.5 to 0.7) <i>I</i> <sup>2</sup> =0.0% 1 study	-0.3 (-1.0 to 0.5) <i>I</i> <sup>2</sup> =99.6% 3 studies	-0.5 (-1.4 to 0.4) <i>I</i> <sup>2</sup> =0.0% 3 studies		Met	1.9 (-11.9 to 15.7)	-0.9 (-5.0 to 3.2)
TZD			3.9 (-1.3 to 9.1) <i>I</i> <sup>2</sup> =0.0% 1 study			-3.4 <sup>a</sup> (-4.2 to -2.6) <i>I</i> <sup>2</sup> =0.0% 3 studies		-1.7 <sup>a</sup> (-2.4 to -1.1) <i>I</i> <sup>2</sup> =82.1% 5 studies		TZD	2.1 (-4.2 to 8.4)
Met+TZD								0.0 (-1.9 to 2.0) <i>I</i> <sup>2</sup> =74.7% 3 studies	3.6 <sup>a</sup> (0.8 to 6.4) <i>I</i> <sup>2</sup> =0.0% 1 study		Met+TZD